RYBREVANT FASPRO™ Receives FDA Approval for First-Line EGFR-Mutated NSCLC
December 26, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
N/A
Synonyms :
upleganan
Class :
Antibiotic, Anti-Microbial
Brand Name :
N/A
Synonyms :
upleganan
Class :
Antibiotic, Anti-Microbial
Dosage Forms & Strengths
Injectable solution (IV/SC)
0.125 mg/kg
Pseudomonas aeruginosa infection and Enterobacteriaceae infection (off-label)
This intravenous (IV) drug (dose studied: 0.125 mg/kg) is undergoing phase I trial study where it is being investigated for the treatment of infections caused due to Pseudomonas aeruginosa and Enterobacteriaceae (gram -ve infections, bacteria)
:
Dose Adjustments
Limited data is available
Safety and efficacy are not established.
Refer to the adult dosing
Actions and Spectrum:
Actions:
Upleganan fights multidrug-resistant Gram-negative bacteria effectively. The minimum inhibitory concentration of the drug against Acinetobacter baumannii and Pseudomonas aeruginosa is determined to be 0.125 mg/L.
Spectrum:
Upleganan shows potent antimicrobial effects on Gram-negative bacteria.
Limited data is available
Black box warning
Limited data is available
Contraindication/Caution:
Contraindications
Hypersensitivity
Cautions
Renal impairment
Hepatic impairment
Pregnancy & breastfeeding
Pregnancy consideration:
No data is available regarding the administration of the drug during pregnancy.
Breastfeeding warnings:
No data is available regarding the excretion of drug in breast milk.
Pregnancy category:
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: No data is available for the drug under this category.
Pharmacology:
Pfizer is testing upleganan in Phase I for Enterobacteriaceae infections. The Phase II entry guideline is a 70% Phase I success rate for such medicines.
Pharmacodynamics:
Upleganan treatment reduces Pa14 and NCTC13301 load in lung tissue and thigh model of neutropenic mice.
Pharmacokinetics:
Limited data is available
Administration:
The route of administration is Intravenous & subcutaneous.
Patient information leaflet
Generic Name: upleganan
Why do we use upleganan?
Upleganan targets gram-negative bacterial infections like Pseudomonas aeruginosa, Acinetobacter baumanii, & carbapenem-resistant Enterobacteriaceae.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
